Related Experiment Video
Updated: Jun 24, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Accomplishments in 2007 in the management of hepatobiliary cancers
Anthony T C Chan1, Yoji Kishi, Stephen L Chan
1The Department of Clinical Oncology at the Sir Y.K. Pao Centre for Cancer, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, State Key Laboratory in Oncology in South China, The Chinese University of Hong Kong, Hong Kong, China.
Abstract:
Hepatocellular CarcinomaOverview of the Disease IncidencePrognostic or Predictive FactorsCurrent Therapy Standards SurgeryLocoablative TreatmentSystemic TreatmentAccomplishments and Lack of Accomplishments TherapyMilan Criteria to Select Patients for Liver TransplantBiologic AgentsBiomarkersBasic ScienceWhat Needs To Be DoneFuture Directions Comments on ResearchObstacles to ProgressBiliary Tract CancerOverview of the Disease IncidencePrognostic or Predictive FactorsCurrent Therapy StandardsAccomplishments and Lack of Accomplishments TherapyBiomarkersWhat Needs To Be DoneFuture Directions.
Insights
This review covers hepatocellular carcinoma and biliary tract cancer, detailing their incidence, prognostic factors, and current therapies. It highlights treatment accomplishments, limitations, and future research directions for these liver cancers.
Area of Science:
- Hepatobiliary cancers
- Oncology
- Medical research
Background:
- Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) are significant global health concerns.
- Understanding their incidence, prognostic factors, and therapeutic landscape is crucial for improving patient outcomes.
Purpose of the Study:
- To provide a comprehensive overview of hepatocellular carcinoma and biliary tract cancer.
- To review current therapeutic standards, including surgery, locoablative treatments, and systemic therapies.
- To discuss accomplishments, limitations, and future research directions in HCC and BTC management.
Main Methods:
- Literature review of hepatocellular carcinoma and biliary tract cancer.
- Analysis of current therapy standards and treatment outcomes.
- Identification of prognostic factors and biomarkers.
Main Results:
- Current therapies for HCC include surgery, locoablative treatments, and systemic agents, with the Milan criteria guiding liver transplant selection.
- Biomarkers and basic science research are advancing understanding but face obstacles.
- HCC and BTC share common challenges in incidence, prognosis, and therapy.
Conclusions:
- Significant progress has been made in understanding and treating HCC and BTC, yet challenges remain.
- Further research into biomarkers, novel therapies, and overcoming research obstacles is essential for future advancements.
- Optimizing patient selection for liver transplantation and developing effective systemic treatments are key priorities.
